MeiraGTx
Manufacturing · New York, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
450 E 29th St Fl 14, New York, New York,...Phone Number
(646) 860-7985Website
www.meiragtx.comRevenue
$79.8 MillionStock Symbol
MGTXIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About MeiraGTx
MeiraGTx is a vertically integrated, clinical stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs.Explore more
MeiraGTx Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MeiraGTx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Click to see if MeiraGTx had a recent Job posting/layoffs
Check out if MeiraGTx is spiking on competitors!
Funding: Get notified immidiatlly once MeiraGTx has new funding data
Product Launch: Get notified when MeiraGTx launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
MeiraGTx, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on MeiraGTx recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at MeiraGTx
Check if MeiraGTx has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to MeiraGTx
Compare insights from companies similar to MeiraGTx, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
MeiraGTx is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
MeiraGTx is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about MeiraGTx.
MeiraGTx financials insights
Gather financial insights about MeiraGTx, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Debt
$100M
MeiraGTx Tech Stack
A closer look at the technologies used by MeiraGTx
See more technologies
Most Recent Scoops
Hiring Plans
MeiraGTx has more open roles in Engineering & Technical than it has had at any time in the past 6 months.
Hiring Plans
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
MeiraGTx has entered into an arrangement with Sanofi, under which Sanofi holds rights of first refusal (ROFRs) on MeiraGTx's RiboSwitch and xerostomia programs, granting Sanofi a defined review window to evaluate program data before it is shared with other parties.
Project
Pharmaceuticals, Clinical Operations
MeiraGTx News & Media
MeiraGTx Reports Second Quarter 2026 Financial and Operational Results
LONDON and NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the second quarter ended June 30, 2026, and provided a corporate update.MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
LONDON and NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the Compensation Committee of the Company’s Board of Directors approved equity awards under the Company’s 2026 Employment Inducement Award Plan to a new employee. The equity awards were granted as an inducement material to the new employee entering employment with MeiraGTx in accordance with Nasdaq Listing Rule 5635(cWhat This MeiraGTx Insider Sale Might Mean With Two Drug Filings Near
Stuart Naylor's 4% portfolio reduction follows an 89% one-year stock surge, executed under a pre-scheduled Rule 10b5-1 trading plan adopted in December 2025.MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)
LONDON and NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced that it has entered into an agreement with Oberland Capital Management LLC (Oberland Capital) for an investment of up to $400 million in the Company, including up to $375 million in non-dilutive capital for capped royalty payments on certain products and up to $25 million in equity.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MeiraGTx
Sign Up For FreeTo access detailed company insights
MeiraGTx is a vertically integrated, clinical stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs.... Read More
